
Our team of overcaffeinated scientists is currently wrestling with words (and possibly a few rogue pipettes).

Stay tuned — brilliance is brewing… ☕⚡

Quarterly Update: June 2026 Highlights

We're pleased to share the recording of our recent webinar, "Bioanalysis of Oligonucleotide Therapeutics via Nucleic Acid Nanorobotic Platform," hosted by the Oligonucleotide Therapeutics Society in May.

Bioanalysis of Oligonucleotide Therapeutics via Nucleic Acid Nanorobotic Platform | Tarin Taleb

In this session, our R&D Scientist, Tarin Taleb, introduces our Nucleic Acid Nanorobotics (NANs) platform, explaining how it enables sensitive, robust, and versatile bioanalysis of oligonucleotide therapeutics. The webinar covers the technology's underlying mechanism, key performance characteristics, and its potential to address some of the field's most pressing analytical challenges.

The presentation also showcases two collaborative case studies that mark an important step in translating toehold-mediated strand displacement (TMSD) from a theoretical concept into a validated bioanalytical approach. To our knowledge, these represent the first commercial assay applications driven by TMSD.

Case Study 1, conducted in collaboration with AstraZeneca's team in Sweden, demonstrates the first direct plasma detection of antisense oligonucleotides (ASOs) using TMSD. The study validates the NAN platform in mouse plasma, assessing key performance metrics including accuracy, precision, reproducibility, and dilutional linearity.

Case Study 2, completed with the Nucleic Acid Therapy Accelerator in Oxford, applies the platform to the novel abcDNA ASO chemistry. Through murine plasma and liver pharmacokinetic analysis, the study demonstrates a robust, modification-tolerant approach for the sensitive and reliable quantification of chemically modified oligonucleotides.

Together, these studies highlight how the NAN platform has evolved beyond proof of concept into a practical, high-performance solution for oligonucleotide bioanalysis.

The webinar also explores how the platform is being extended to increasingly complex applications, including siRNA quantification, brain pharmacokinetic studies, antibody oligonucleotide conjugates, and short ASOs.

The session concluded with a lively Q&A covering topics such as compatibility with diverse ASO and siRNA chemistries, tissue homogenisation strategies, cellular localisation, supported tissue types, and quantification across different biological matrices.

Thank you to everyone who joined us and contributed to the discussion. We look forward to hosting more webinars in the future.

Tarin Taleb graduated from Durham University, in 2021, with a bachelor’s degree in biomedical sciences. After one year at Cambridge Research Biochemicals she joined Nanovery in 2022. Over the past four years she has been pivotal in the development of Nanovery’s Nucleic Acid Nanorobotics (NAN) platform. Her expertise covers molecular biology, DNA nanotechnology, and assay development. She currently leads optimisation of NAN assays, integrating them with complex biological matrices, and refining buffer systems to ensure assay performance for a diverse range of oligonucleotide therapeutics.

Oligonucleotide Therapeutics Society (OTS) Webinar by Tarin Taleb

Quarterly Update: April 2026 Highlights (coming soon)

As the days grow shorter and colder, the season has been anything but quiet. This quarter has been about hard work - in our labs and out on the road - as a busy run of conferences, a wave of new business and collaborations, and a landmark first publication with a major pharma partner all came together at once. It's been one of our most eventful periods yet. Here's a round-up of what we've been up to.

1. Our First Peer-Reviewed Publication with AstraZeneca

We're incredibly proud to share that our collaborative study with AstraZeneca has been published - a genuine milestone for Nanovery and for Nucleic Acid Nanorobotics as a whole. It's the first time our platform has been shown in the peer-reviewed literature, alongside a global pharma partner, to perform pharmacokinetic bioanalysis of antisense oligonucleotides directly in plasma.

What makes the result meaningful is its simplicity. As ASO and siRNA pipelines expand, bioanalysis has increasingly become a bottleneck: the established approaches tend to be intricate, labour-intensive, and dependent on specialist expertise. Our NAN assay takes a different route - a streamlined two-step workflow with no extraction steps and no enzymes, built on a programmable molecular interaction that produces a fluorescent readout in proportion to ASO concentration. The study demonstrates the sensitivity, precision, and accuracy needed across the PK range, and - importantly - the assay was transferred to AstraZeneca's own laboratory, where their team independently qualified its performance against key bioanalytical standards.

For our partners, this is the clearest signal yet of what the platform can do in real-world hands: a method that travels, that a pharma team can run themselves, and that stands up to independent scrutiny.

You can access the publication here: Nucleic acid nanorobot assay for accurate and simplified ASO quantification in mouse plasma

2. Oligonucleotide Therapeutics Society (OTS) Annual Meeting, Budapest

Estela and Alex represented Nanovery at the OTS Annual Meeting in Budapest - the premier global gathering of the oligonucleotide community. It's a genuinely cross-disciplinary forum, drawing together chemistry, delivery, biology, immunology, and clinical medicine, with over 900 participants from 25 countries and more than 400 institutions across four days of sessions.

For a field-shaping meeting like this, the value is as much in the conversations between talks as in the science on stage. It's where new collaborations start, and where we get to test how our thinking maps onto the community's most pressing challenges as therapies move from lab to clinic.

Jurek and Estela were in Vienna for BIO-Europe, one of the largest partnering events in the industry. With a packed schedule of meetings across a broad range of relevant companies, it was an intensive and productive few days of building relationships and scoping where we can help. The conference also served up a memorable networking dinner at the Hofburg, Vienna's grand baroque palace - a fitting backdrop for the kind of conversations that turn into partnerships.

4. BioTools Innovator Capstone, San Diego

Jurek travelled to San Diego for the capstone event of the BioTools Innovator programme. The panel discussions were excellent, and the calibre of the room was high throughout - our only regret is that it was a single day, because we'd happily have spent longer with that crowd. We made good use of the wider trip too, meeting local companies across the spectrum from small biotechs to large pharma. Those conversations went well, and it looks like several new collaborations will grow out of them.

Roma represented Nanovery at the European Bioanalysis Forum, held under the fitting motto "Fearless Science Driven by Curiosity – Guided by Data." Roma reconnected with existing pharma collaborators and met a number of new potential partners, including large CROs who expressed real interest in working with us. We're looking forward to continuing those discussions and seeing where they lead.

If this quarter had a through-line, it was momentum: a first major publication behind us and a growing set of collaborations ahead. Into the new year, our priority stays exactly where it's always been - delivering on our promise to build the best bioanalysis platform for oligonucleotide therapeutics.

If you're working with ASOs, siRNA, or emerging oligonucleotide modalities and want simpler, more adaptable bioanalysis, we'd love to talk - we're actively supporting partners in this space.

Thanks for following our journey. You can always reach us on LinkedIn or contact the team directly. Exciting times ahead!

Quarterly Update: December 2025 Highlights

As the year continues to gather pace, the past quarter has been about sharpening focus: on our science, on how we work with partners, and on where Nucleic Acid Nanorobotics can have the greatest long-term impact. From deep technical discussions on the future of molecular programming to meeting partners on the ground in the US, it’s been an energising and productive period for the team. Here’s a snapshot of what we’ve been up to.

1. Shaping the Next Decade of Molecular Programming in Seattle

Earlier this quarter, we attended Molecular Flight Plan in Seattle - a focused meeting bringing together leading experts in molecular programming, DNA nanotechnology, and related disciplines. The goal was ambitious: to help shape a shared vision for the field's direction over the next 10 years.

These discussions went well beyond near-term applications, covering foundational challenges, emerging opportunities, and the kinds of tools and infrastructure the community will need to unlock the next wave of progress. Being part of this conversation reinforces our belief that programmable nucleic acid systems will play a central role in future biomedicine, therapeutics and diagnostics, and that building robust, deployable platforms now is critical.

For our partners, this means we’re not just solving today’s problems, but actively designing technology with longevity and scalability in mind.

2. A One-Minute Introduction to Nanovery and NANs

As part of the BioTools Innovator programme, we released a short, one-minute video introducing Nanovery and our Nucleic Acid Nanorobotics platform.

In a deliberately concise format, the video captures the essence of Nanovery and NANs, and why this approach enables simpler, faster, and more adaptable bioanalysis for oligonucleotide therapeutics.

Nanovery: Overview

If you’re new to Nanovery, it’s a quick way to understand what we do. If you’ve been following our journey, it reflects how far the platform has matured.

3. A Fruitful Trip to Boston: Conferences and Conversations

Boston was a major focus this quarter. Over a single trip, we attended three key conferences:

4th Oligonucleotides Analytical Development & CMC Summit

Across these meetings, we engaged in detailed discussions around PK bioanalysis, CNS delivery challenges, assay sensitivity, and the growing complexity of oligonucleotide modalities. Just as importantly, we spent time meeting with local biotech and pharma companies across the Boston area, deepening existing relationships and starting new ones.

These conversations continue to shape how we prioritise new capabilities within the NANs platform, ensuring what we build maps directly to real-world needs in discovery and development.

This quarter also marked an important internal milestone: Estela joined Nanovery to lead and strengthen our business development operations.

She’s integrated incredibly quickly and has already helped streamline how we engage with partners - from first conversations, through scoping, to project delivery. The result is a clearer, smoother, and more predictable experience for companies working with us.

As our science scales, making Nanovery easy to work with is just as important as technical performance. Estela’s arrival has allowed the wider team to focus even more sharply on what we do best: building and deploying high-quality nanorobotic assays that solve hard bioanalytical problems.

The coming months will see us continue to expand the scope of the NANs platform, progress ongoing partner projects, and share more of what we’re learning along the way. With stronger foundations - both scientifically and operationally - we’re excited about what this next phase enables.

If you’re working with ASOs, siRNA, or emerging oligonucleotide modalities and looking for simpler, more adaptable bioanalysis, we’re actively supporting partners in this space and would be happy to talk.

Thanks for following our journey, exciting times ahead!

Quarterly Update: September 2025 Highlights

As the days grow longer and the lab gets sunnier, we’ve been making strides across science, strategy, and summer refreshments. This quarter has brought new partnerships, fresh faces, and more momentum for our platform. Here’s a round-up of what we’ve been up to.

We’re excited to announce that we’ve secured new investment from Northstar Ventures and Smartlink Partners. Their support comes at a pivotal time, as we focus on reaching critical commercial milestones and expanding our outreach to leading pharmaceutical companies. This funding will allow us to strengthen our technology offering, grow our business development capabilities, and accelerate our work with partners tackling the toughest challenges in RNA therapeutics.

We're particularly grateful to have investors who not only understand the complexity of what we’re building, but who also share our long-term vision. Their belief in our mission - and in the potential of Nucleic Acid Nanorobotics - is a strong vote of confidence as we move into this next phase of growth.

2. Innovate UK Grant to Advance Molecular Programming

We’re proud to share that we’ve been awarded a new grant from Innovate UK to support the continued development of our molecular programming and computational modelling capabilities. At Nanovery, we’re always striving to deliver novel assays and results faster. A critical part of this is being able to accurately predict how our nanorobots will behave, before they’re built. With stronger in silico modelling, we can now get to optimised assays within the first or second iteration, dramatically reducing turnaround times.

Computational design sits at the heart of our platform, and this grant will help us expand what’s possible. Combined with the arrival of two experienced computational scientists, Karol Kaszuba and Alex Punter, we’re in a stronger position than ever to accelerate assay development across virtually every project we run.

This June, Ennio represented Nanovery at the SLAS Europe 2025 Conference in Hamburg, which is a leading event for life sciences innovation, automation, and drug discovery technologies. With over 1,000 attendees from across biotech and pharma, the conference provided a valuable platform to engage with scientists and technology developers shaping the future of research tools.

Ennio showcased our work in nucleic acid nanorobotics for bioanalysis, highlighting how Nanovery’s approach is helping to solve long-standing challenges in oligonucleotide detection. From technical conversations to new connections, it was a fantastic opportunity to share our story with a broader European audience.

4. Selected for BioTools Innovator 2025 – A Global Platform for the Future of Biotech Tools

We’re honoured to announce that Nanovery has been selected to join the BioTools Innovator 2025 programme: a highly competitive, industry-backed accelerator dedicated specifically to companies building transformative life science tools and platforms. Backed by a coalition of strategic partners from across the biotech and pharmaceutical industries, the programme is uniquely tailored to support companies like ours that are solving critical unmet needs in research and drug development.

To be chosen from a global pool of applicants is a massive opportunity for us. It validates the work we’ve done so far, and opens new doors as we scale our commercial efforts. The programme kicked off in Mountain View, California, earlier this month, where we joined the 2025 cohort and began building relationships with mentors, investors, and potential customers from across the sector. We’re excited about what’s ahead and grateful for the support and belief from the BioTools Innovator team and their partners.

5. Elderflower Cordial and the Science of Teamwork

Long summer days in the lab call for focus, stamina... and sometimes, a bit of creativity. This month, the team came up with a new way to bring a little refreshment to our workspace: a homemade elderflower cordial, now quietly replacing the standard water cooler.

It’s a small detail, but it speaks to something bigger: our commitment to making the lab a place where ideas flow as freely as conversations. Whether discussing assay optimisation or modelling improvements, these impromptu huddles are often where the best thinking starts.

We take our science seriously, and our mission even more so. Creating a space where people want to be, where they’re supported, engaged, and collaborating, is a big part of why we’re able to move fast and solve hard problems together.

As summer progresses, we’re continuing to build, test, and deploy better tools for the RNA therapeutics community. Whether you’re working on ASOs, siRNA, or something even more ambitious - we’d love to hear from you.

Thanks for following our journey. You can always reach us on LinkedIn or contact the team directly!

Quarterly Update: June 2025 Highlights

We’re excited to share our first quarterly update of 2025. With winter receding and spring just around the corner, we’ve hit the ground running. The first months of the year have brought steady progress and new opportunities, especially in our Nucleic Acid Nanorobotics (NANs) platform. Our team’s dedication and expertise continue to fuel these advancements, and it’s been heartening to see our hard work pay off as the season changes.

We look forward to sharing our milestones and what’s on the horizon for the rest of the year.

We recently published a behind-the-scenes video detailing how our NANs are designed and developed – from in silico modeling to laboratory construction.

Inside Nanovery: How We Build Nucleic Acid Nanorobotics for Bioanalysis

Leveraging our growing computational pipeline, we are continually refining our approach. Thanks to our iterative design, build, test, and learn cycle, each experiment enriches our understanding, generates new datasets and sharpens our predictive algorithms. This means we can refine our nanorobot designs faster and more reliably—well before we start assembling them in the lab—ultimately streamlining the entire development process. For our customers, this translates into quicker, more robust assay development, allowing them to see reliable results sooner.

2. Attending the RNA Therapeutics Conference

In February, our team attended the RNA Therapeutics Conference in London. We had the privilege of learning from industry-leading presentations by Eli Lilly, GSK, Moderna, AstraZeneca, Roche, and Johnson & Johnson, among others. We also formed valuable connections with fellow attendees, potentially paving the way for new collaborations that could further accelerate our work in RNA therapeutics bioanalysis.

Our second project with a large global pharmaceutical partner kicked off towards the end of last year, and it’s progressing smoothly. We plan to publish the outcomes of our existing projects to showcase the remarkable results we’re generating. Additionally, we’re in active discussions with four other major pharmaceutical companies regarding potential collaborations. We look forward to sharing more details as these partnerships develop.

4. Breakthroughs in Double-Stranded siRNA Analysis

We’ve made significant progress in our platform’s capability to analyze double-stranded siRNA molecules and are currently piloting this solution with select biotech partners. Additionally, our capacity to support oligonucleotide therapies with chemical modifications (including LNA, fluoro, MOe, and OME modifications) continues to strengthen, enabling us to provide more comprehensive analysis and support. If you’re working with novel or more exotic chemical modifications and find it challenging to detect or quantify your candidate molecules, we encourage you to reach out to us.

Toward the end of last year, we hosted a webinar titled “New Frontiers in ASO and siRNA Bioanalysis.” We thoroughly enjoyed the insightful conversations with established pharma and emerging biotech companies, and we look forward to hosting similar events soon. You can watch the recording of the webinar here:

NANOVERY WEBINAR: New Frontiers in ASO and siRNA Bioanalysis

We continue to foster strong connections with Newcastle University and Durham University, where our founders, lab scientists, and PhD students have recently delivered presentations to biotech and life science students. Engaging with the next generation of innovators is integral to our mission and aligns with our grant dissemination commitments. By sharing our journey, challenges, and discoveries, we aim to spark curiosity, inspire budding scientists, and help build a thriving biotech ecosystem—ultimately benefiting the entire research and deep tech community.

As we move further into 2025, we remain committed to pushing the boundaries of our nanorobotics platform and forging meaningful collaborations across the biotechnology and pharmaceutical sectors. Thank you for following our progress, and stay tuned for more updates in the coming months.

For inquiries or more information, feel free to contact our team or explore our resources online. We look forward to continuing this journey with you.

Quarterly Update: March 2025 Highlights

As part of our ongoing growth and development programme, we are pleased to announce the appointment of Jurek Kozyra, Founder and Chief Business Officer, to the CEO role.
 
Mark Chadwick, the outgoing CEO, has guided the company through its transition from a research-led organisation to a commercially focused one and will transition to a role as board advisor. We would like to thank Mark for his leadership and guidance as CEO, his continued commitment to the success of Nanovery, and his ongoing support of the board in his new role.

Comments from Mark:

I am today announcing my transition from part time CEO of Nanovery to Senior Board Advisor. As a company, we have made amazing strides in refocusing our Nanorobot platform towards the RNA therapeutics market, including 2 top 10 pharma breakthrough deals and with further projects imminent. However, in a challenging investment environment, I feel this is the way I can continue to best support the company through its next funding round and phase of development. I will always champion the amazing team at Nanovery, who have become very much friends as well as colleagues. I feel sure that they will all continue onwards with courage and fortitude, and achieve great things together!

Comments from Jurek:

The past two years have been an incredible journey of learning and growth for Nanovery. We took bold steps to bring our technology to the forefront, achieving first commercial deals and seeing uptake from leading pharma and biotech companies. These milestones reflect our team's dedication and hard work as we expanded our capabilities and refined our focus. As Chief Business Officer, I had the privilege of working closely with our partners and customers to demonstrate the potential of Nanovery’s platform. Stepping up into the CEO role, I’m excited to continue driving this mission forward as we enter a new phase of growth.

Jurek Kozyra Named CEO as Nanovery Enters Next Growth Phase

Most Popular

We are a data driven company using DNA nanotechnology and AI to scale up testing of nucleic acids for powerful insights from valuable samples.